EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome

Nasikarn Angkasekwinai iD, Yupin Suputtamongkol, Wiwit Tantibhedhyangkul, Nattawat Onlamoon, Pakpoom Phoompoung, Manop Pithukpakorn, Ekkapun Karuphong, Pawana Pusuwan, Pornpimon Angkasekwinai

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Nasikarn Angkasekwinai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Tha…. Hauptthemen laut MEDLINE: Autoantibodies, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Systems Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Currently, there is no effective treatment for adult-onset immunodeficiency (AOID) syndrome with anti-interferon-gamma autoantibodies (anti-IFN-γ-auto-Abs). This study aimed to investigate the effectiveness of bortezomib (BTZ) for decreasing anti-IFN-γ-auto-Abs.

Methods

A pre- and post-intervention study was conducted from February 2017 through June 2019 at Siriraj Hospital (Bangkok, Thailand). Five patients were invited to receive once-weekly BTZ (1.3 mg/m2 body surface area) subcutaneously for 8 weeks followed by oral cyclophosphamide (1 mg/kg/d) for 4 months. The primary outcomes were the difference in antibody level at 8 and 48 weeks compared with baseline and the incidence of serious adverse events (AEs). The secondary outcome was the occurrence of opportunistic infections (OIs) during the 72 weeks after starting BTZ.

Results

The median patient age was 46 years (range, 34–53). All patients had 3–5 OIs prior to enrollment. All patients were receiving antimycobacterial agents for treatment of nontuberculous mycobacterial infection at enrollment. There was no significant difference in the mean optical density of auto-Abs at 8 weeks (3.73 ± 0.72) or 48 weeks (3.74 ± 0.53) compared with baseline (3.84 ± 0.49; P = .336 and P = .555, respectively). However, after serum dilution, the antibody titer nonsignificantly decreased 8–16 weeks after BTZ initiation (P = .345). Ten OIs were observed 24–72 weeks after BTZ initiation.

Conclusions

Treatment with BTZ followed by cyclophosphamide yielded no significant decrease in antibody titer levels, and 10 OIs were observed during 24–72 weeks of BTZ treatment. No serious AEs were observed. Combining rituximab with BTZ is likely necessary to prevent generation of new autoantibody-producing plasma cells. Clinical Trials Registration. NCT03103555.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesImmunologic Deficiency SyndromesAdultHumansMiddle AgedBortezomibThailandInterferon-gammaCyclophosphamide

Stichwörter der Autor:innen

anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency (AOI…bortezomibefficacyopportunistic infectiontreating

Substanzen

AutoantibodiesBortezomibInterferon-gammaCyclophosphamide

Autor:innen und Institutionen

  • Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Research Group in Immunobiology and Therapeutic Sciences, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Medical Genetics, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Nasikarn Angkasekwinai

Förderung

  • Health Systems Research Institute

Zitieren

APA

Angkasekwinai, N., Suputtamongkol, Y., Tantibhedhyangkul, W., Onlamoon, N., Phoompoung, P., Pithukpakorn, M., Karuphong, E., Pusuwan, P., & Angkasekwinai, P. (2024). Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad676

Vancouver

Angkasekwinai N, Suputtamongkol Y, Tantibhedhyangkul W, Onlamoon N, Phoompoung P, Pithukpakorn M, et al. Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad676

BibTeX
@article{Angkasekwinai2024,
  author = {Angkasekwinai, Nasikarn and Suputtamongkol, Yupin and Tantibhedhyangkul, Wiwit and Onlamoon, Nattawat and Phoompoung, Pakpoom and Pithukpakorn, Manop and Karuphong, Ekkapun and Pusuwan, Pawana and Angkasekwinai, Pornpimon},
  title = {Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad676}
}
Kostenlos starten →